Post-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2023’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
- The report reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Post-Traumatic Stress Disorder (PTSD) therapeutics and enlists all their major and minor projects
- The report assesses Post-Traumatic Stress Disorder (PTSD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Addex Therapeutics LtdAelis Farma SAS
Aision Biotechnologies Inc
Algernon Pharmaceuticals Inc
Allied Corp
Alto Neuroscience Inc
Alzamend Neuro Inc
Amorsa Therapeutics Inc
Anagin Inc
Ananda Scientific Inc
Apex Labs Ltd
AriBio Co Ltd
Artelo Biosciences Inc
Avicanna Inc
Better Life Pharmaceuticals Inc
Bionomics Ltd
Bionorica SE
BnH Research
Boehringer Ingelheim International GmbH
Braxia Scientific Corp
Bright Minds Biosciences Inc
Centre for Addiction and Mental Health
Chemestmed OU
Chronos Therapeutics Ltd
Compass Pathways Plc
Corcept Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Delix Therapeutics Inc
Eli Lilly and Co
EmpathBio
Empyrean Neuroscience Inc
Emyria Ltd
Endosane Pharmaceuticals GmbH
Engrail Therapeutics Inc
EpiVario Inc
Ethicann Pharmaceuticals USA Inc
Evecxia Therapeutics Inc
Exxel Pharma Inc
F. Hoffmann-La Roche Ltd
GABA Therapeutics Inc
H. Lundbeck AS
Halucenex Life Sciences Inc
Healis Therapeutics LLC
Idorsia Pharmaceutical Ltd
Innovation1 Biotech Inc
Jazz Pharmaceuticals Plc
Johnson & Johnson
Kdac Therapeutics Inc
Kinnov Therapeutics
Lactocore Inc
Lennham Pharmaceuticals Inc
London Research & Pharmaceuticals Ltd
MD Healthcare Inc
Mindstate Design Labs
Mydecine Innovations Group Inc
Nanomerics Ltd
National Institute on Alcohol Abuse and Alcoholism
Neuritek Therapeutics AG
NeuroNascent Inc
Neurorive Inc
Neurovation Labs Inc
Neurxstem Inc
NRX Pharmaceuticals Inc
NW PharmaTech Ltd
Omeros Corp
One World Cannabis Ltd
Optimi Health Corp
Otsuka Pharmaceutical Co Ltd
PharmAla Biotech Inc
PharmaTher Holdings Ltd
Phoenix PharmaLabs Inc
Protagenic Therapeutics Inc
Psy Therapeutics Inc
PsyBio Therapeutics Corp
Psycheceutical Inc
Rest Therapeutics SAS
Sage Therapeutics Inc
Sanofi
Scientus Pharma Inc
Seelos Therapeutics
Inc.
Silo Pharma Inc
Soroka University Medical Center
Synendos Therapeutics AG
Tokyo University of Science
Tonix Pharmaceuticals Holding Corp
Transcend Therapeutics Inc
University of Haifa
University of Miami Miller School of Medicine
Virpax Pharmaceuticals Inc
Wake Network Inc
Woke Pharmaceuticals Pty Ltd